Butel cites the highlight of her career as the work she did regarding a viral contaminant in the early live polio vaccine. Proud to have contributed fundamental research to the biology of tumor viruses and their cancer-causing mechanisms, Dr. Butel began her career with Baylor as an assistant professor in 1968, rising to full professor by 1976. The director of the Baylor Center for AIDS Research from 1994 to 2005, she was also the head of the division of molecular virology at Baylor College of Medicine from 1989 to 1999.
Duncan Comprehensive Cancer Center, the director of the Baylor-UT Houston Center for AIDS Research from 2005 to 2015 and the chair of the department of molecular virology and microbiology from 2000 to 2016. Between 20, she was the leader of a research program in the Dan L. Melnick professor of virology from 1986 to 2018 and the Kyle and Josephine Morrow chair from 2013 to 2018. Having held the role of distinguished service professor from 1995 to 2018, she was also the Joseph L. Butel, PhD, spent her entire career with the Baylor College of Medicine in Houston, Texas, retiring as a distinguished service professor emeritus in 2018. Additional studies are needed to determine whether EBV-specific CD4+ and CD8+ cells play a role in the pathogenesis of EBV in HIV-1-infected patients receiving HAART.Janet S.
The frequency of EBV detection in blood was associated with lower CD4+ cell counts (P=.03) among HIV-1-infected individuals, although no differences were observed in the EBV DNA loads in blood or saliva samples in the HIV-1-infected group. The mean EBV loads in blood and saliva samples were also higher in HIV-1-infected patients than in HIV-1-uninfected volunteers (P=.001).
11 of 68 patients P=.001) and saliva (55 of 68 vs.
Using a real-time quantitative polymerase chain reaction assay, we demonstrated that significantly more HIV-1-infected patients receiving HAART than HIV-1-uninfected volunteers had detectable EBV DNA in blood (57 of 70 vs. However, little is known of the EBV DNA loads in patients receiving highly active antiretroviral therapy (HAART). Patients with human immunodeficiency virus type 1 (HIV-1) infection are at high risk of developing Epstein-Barr virus (EBV)-associated lymphoma.
0 kommentar(er)
